MCID: PLS009
MIFTS: 51

Plasma Cell Neoplasm

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Plasma Cell Neoplasm

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 12 15 17 71
Plasma Cell Dyscrasia 12 71
Paraproteinemias 43 71
Plasma Cell Tumour 12
Plasmacytic Tumor 12
Multiple Myeloma 71
Plasmacytoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:6536
MeSH 43 D010265
SNOMED-CT 67 71390001
UMLS 71 C0026764 C0030489 C0032131 more

Summaries for Plasma Cell Neoplasm

MalaCards based summary : Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to monoclonal paraproteinemia and plasma cell leukemia. An important gene associated with Plasma Cell Neoplasm is MAEA (Macrophage Erythroblast Attacher), and among its related pathways/superpathways are Innate Immune System and B cell receptor signaling pathway (KEGG). The drugs Phentolamine and Apixaban have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow, and related phenotypes are cellular and hematopoietic system

Related Diseases for Plasma Cell Neoplasm

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 548)
# Related Disease Score Top Affiliating Genes
1 monoclonal paraproteinemia 34.1 SDC1 PAX5 CD79A CD40LG CD38 CD19
2 plasma cell leukemia 33.3 NCAM1 IRF4
3 lymphoid interstitial pneumonia 32.6 SDC1 IL6 CD40LG CD19
4 plasmacytoma 32.4 PVT1 PTPRC PAX5 NCAM1 MYC IRF4
5 extramedullary plasmacytoma 31.5 SDC1 MYOM2 MAEA IRF4 IL6 CD79A
6 myeloma, multiple 31.3 SDC1 PVT1 PTPRC PAX5 NCAM1 MYOM2
7 osteosclerotic myeloma 31.1 MYOM2 MAEA IL6 CD40LG
8 purpura 30.9 IL6 CD79A CD40LG
9 cryoglobulinemia 30.8 IL6 CD79A CD40LG
10 cryofibrinogenemia 30.8 CD79A CD40LG
11 smoldering myeloma 30.8 SDC1 NCAM1 MYOM2 IGHV4-38-2 CD40LG CD38
12 polyclonal hypergammaglobulinemia 30.7 MYOM2 IL6 CD40LG
13 plasmablastic lymphoma 30.7 PTPRC MYC CD38
14 exanthem 30.7 IL6 ICOSLG CD40LG CD19
15 indolent myeloma 30.7 MYOM2 IL6
16 macroglobulinemia 30.7 SDC1 PAX5 IL6 CD40LG
17 lung lymphoma 30.6 PAX5 IRF4 CD79A
18 amyloidosis 30.6 MYOM2 IL6 CD40LG B2M
19 gamma heavy chain disease 30.5 SDC1 IGHV4-38-2 CD40LG
20 anemia, autoimmune hemolytic 30.5 IGHV4-38-2 ICOSLG CD40LG CD19
21 interstitial nephritis 30.5 ICOSLG CD40LG B2M
22 heavy chain disease 30.5 MYOM2 CD79A CD40LG
23 skin disease 30.4 IL6 ICOSLG CD79A CD40LG B2M
24 syphilis 30.4 CD79A CD40LG B2M
25 agammaglobulinemia 30.3 IL6 ICOSLG CD79A CD40LG CD19
26 celiac disease 1 30.3 NCAM1 IL6 ICOSLG CD79A CD40LG
27 central nervous system lymphoma 30.3 PAX5 MYC IL6
28 multicentric castleman disease 30.3 SDC1 PAX5 IL6 CD79A
29 toxoplasmosis 30.3 IL6 CD79A CD40LG
30 alpha chain disease 30.3 MYOM2 CD79A CD40LG CD19
31 lymphoma, hodgkin, classic 30.2 PVT1 PTPRC PAX5 IRF4 ICOSLG
32 acquired immunodeficiency syndrome 30.2 MYC IL6 CD79A CD40LG CD38 B2M
33 b-cell lymphoma 30.2 PVT1 PTPRC PAX5 MYC MIR181A1 IRF4
34 arteries, anomalies of 30.2 MIR181A1 IRF4 IL6 ICOSLG
35 follicular lymphoma 30.2 PAX5 MYC MIR181A1 IRF4
36 solitary osseous plasmacytoma 30.1 SDC1 NCAM1 MYOM2 MAEA CD79A CD38
37 marginal zone b-cell lymphoma 30.1 PAX5 IRF4 IGHV4-38-2 CD79A CD40LG CD19
38 pancytopenia 30.1 PTPRC NCAM1 IRF4 IL6 CD40LG CD19
39 peripheral nervous system disease 30.1 MYOM2 IL6 ICOSLG CD40LG B2M
40 immune deficiency disease 30.1 PTPRC IRF4 IL6 ICOSLG CD79A CD40LG
41 eye disease 30.0 PTPRC MYC MIR181A1 IRF4 IL6 ICOSLG
42 bone disease 29.9 SDC1 IL6 ICOSLG B2M
43 burkitt lymphoma 29.9 PVT1 PAX5 MYC IRF4 IL6 CD40LG
44 lymphocytic leukemia 29.9 PTPRC PAX5 MYC CD40LG CD38 B2M
45 combined t cell and b cell immunodeficiency 29.9 PTPRC IRF4 IL6 ICOSLG CD40LG CD19
46 lymphoma, mucosa-associated lymphoid type 29.8 SDC1 PTPRC PAX5 MYC IRF4 IGHV4-38-2
47 monoclonal gammopathy of uncertain significance 29.8 SDC1 NCAM1 MYOM2 MYC IL6 IGHV4-38-2
48 lymphoma 29.8 PVT1 PTPRC PAX5 MYC IRF4 IL6
49 leukemia, acute lymphoblastic 29.8 PTPRC PAX5 IRF4 CD38 CD19
50 mantle cell lymphoma 29.7 PTPRC PAX5 MYC IL6 CD40LG CD19

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Deficiency Anemia Heart Disease
Monoclonal Paraproteinemia Neutropenia
Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm

Symptoms & Phenotypes for Plasma Cell Neoplasm

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.07 B2M CD19 CD38 CD40LG CD79A IL6
2 hematopoietic system MP:0005397 9.97 B2M CD19 CD38 CD40LG CD79A IL6
3 immune system MP:0005387 9.77 B2M CD19 CD38 CD40LG CD79A IL6
4 neoplasm MP:0002006 9.28 B2M CD19 CD79A IL6 IRF4 MYC

Drugs & Therapeutics for Plasma Cell Neoplasm

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 664)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phentolamine Approved Phase 4 50-60-2 5775
2
Apixaban Approved Phase 4 503612-47-3 10182969
3
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
4
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
5
Epirubicin Approved Phase 4 56420-45-2 41867
6
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
7
Liraglutide Approved Phase 4 204656-20-2 44147092
8
Glucagon Approved Phase 4 16941-32-5
9
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
10
Pirarubicin Investigational Phase 4 72496-41-4
11 Anti-Retroviral Agents Phase 4
12 Anti-HIV Agents Phase 4
13 Plerixafor octahydrochloride Phase 4
14 Vasodilator Agents Phase 4
15 Antithrombins Phase 4
16 Serine Proteinase Inhibitors Phase 4
17 Antithrombin III Phase 4
18 Factor Xa Inhibitors Phase 4
19 Polymethyl Methacrylate Phase 4
20 penicillins Phase 4
21 Penicillin G Benzathine Phase 4
22 Penicillin G Procaine Phase 4
23 Hypoglycemic Agents Phase 4
24 Incretins Phase 4
25 Glucagon-Like Peptide 1 Phase 4
26 Mitogens Phase 4
27 Hematinics Phase 4
28 Epoetin alfa Phase 4 113427-24-0
29 Ferric Compounds Phase 4
30
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
31
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
32
Pamidronate Approved Phase 3 40391-99-9 4674
33
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
35
deoxycholic acid Approved Phase 3 83-44-3 222528
36
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
37
Sulfamethoxazole Approved Phase 3 723-46-6 5329
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
39
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
40
Ethanol Approved Phase 3 64-17-5 702
41
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
42
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
43
Ifosfamide Approved Phase 3 3778-73-2 3690
44
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
45
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
46
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
47
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
48
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
49
Calcium carbonate Approved, Investigational Phase 3 471-34-1
50
Amitriptyline Approved Phase 3 50-48-6 2160

Interventional clinical trials:

(show top 50) (show all 2834)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
2 Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
3 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
4 Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
5 A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
6 Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma Completed NCT00622505 Phase 4 zoledronic acid
7 Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability Completed NCT00257114 Phase 4 bortezomib
8 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
9 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
10 Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study Completed NCT02268890 Phase 4 Bortezomib
11 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
12 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
13 Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
14 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
15 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
16 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban
17 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
18 REmoval of Free Light Chains in Hemodialysis Patients Without Multiple Myeloma. A Crossover COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
19 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
20 Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects Completed NCT02056210 Phase 4 Mozobil
21 Influenza Vaccination in Plasma Cell Dyscrasias Recruiting NCT04080531 Phase 4
22 Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study Recruiting NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
23 A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Recruiting NCT03768960 Phase 4 Daratumumab
24 Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study Recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
25 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Recruiting NCT02286830 Phase 4 Zoledronic acid
26 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
27 An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
28 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
29 A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone
30 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Recruiting NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
31 Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group Active, not recruiting NCT01087008 Phase 4 zoledronic acid
32 An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
33 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
34 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Not yet recruiting NCT02920190 Phase 4 Liraglutide
35 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
36 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
37 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
38 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
39 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
40 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
41 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
42 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
43 Study of Cyclophosphamide,Liposome Doxorubicin Dexamethasone(CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
44 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
45 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
46 A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
47 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
48 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
49 A Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma Unknown status NCT02916420 Phase 3 Pomalidomide;Dexamethasone
50 Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma Unknown status NCT00932217 Phase 3 filgrastim;lenograstim

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
bortezomib
carfilzomib
Carmustine
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Melphalan
Melphalan hydrochloride
panobinostat
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Thalidomide
ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: paraproteinemias

Genetic Tests for Plasma Cell Neoplasm

Anatomical Context for Plasma Cell Neoplasm

MalaCards organs/tissues related to Plasma Cell Neoplasm:

40
Bone, T Cells, Bone Marrow, B Cells, Myeloid, Testes, Breast

Publications for Plasma Cell Neoplasm

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 1275)
# Title Authors PMID Year
1
Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes. 61
31736101 2020
2
An autopsy case of amyloid tubulopathy exhibiting characteristic spheroid-type deposition. 61
31932919 2020
3
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report. 61
31918690 2020
4
A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. 61
31940000 2020
5
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis. 61
31815313 2019
6
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. 61
31844041 2019
7
Differential diagnosis between bone relapse of breast cancer and lambda light chain multiple myeloma: role of the clinical biochemist. 61
30799772 2019
8
Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α. 61
31650289 2019
9
Cutaneous Nodular Amyloidosis: A Disfiguring Aspect of the Face. 61
31268923 2019
10
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. 61
31748515 2019
11
Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016: An observational study. 61
31702615 2019
12
Amyloid-Associated Alopecia: A Reappraisal Including Its Pathophysiology. 61
30839340 2019
13
The spectrum of malignancies presenting with neurological manifestations: A prospective observational study. 61
31803680 2019
14
Current opinions in nephrology and hypertension: kidney transplantation in patients with plasma cell dyscrasias. 61
31403474 2019
15
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. 61
31780812 2019
16
Cardiac amyloidosis: the need for early diagnosis. 61
31359320 2019
17
Plasma cell leukemia with plasmablastic morphology in a dog. 61
31609183 2019
18
Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells. 61
31767606 2019
19
Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias. 61
31587789 2019
20
Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. 61
31207062 2019
21
Paraprotein implicated in hardware failures in nucleic acid testing of blood donors. 61
31777099 2019
22
Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding. 61
31379060 2019
23
The Evolution of Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant Recipients. 61
31723584 2019
24
MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1. 61
31452083 2019
25
Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. 61
31734019 2019
26
Extramedullary Plasmacytoma Involving the Trachea: A Case Report and Literature Review. 61
31266689 2019
27
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents? 61
31255588 2019
28
Monoclonal Gammopathy of Renal Significance and its Associated Experimental Models. 61
31471332 2019
29
POEMS syndrome: a rare cause of adrenal insufficiency in a young male. 61
31967972 2019
30
Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation. 61
31320253 2019
31
The epidemiology of amyloidosis in Queensland, Australia. 61
31148162 2019
32
[Paraproteins. A review]. 61
31859969 2019
33
A case report of recurrent membranoproliferative glomerulonephritis after kidney transplantation due to ventriculoatrial shunt infection. 61
31382904 2019
34
Cardiac Amyloidosis: A Case Series from India. 61
31562714 2019
35
Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide. 61
31365665 2019
36
PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression. 61
31053880 2019
37
Myeloma of Laryngeal Cartilage: Literature Review and Case Study. 61
31284752 2019
38
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. 61
31012139 2019
39
Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry. 61
31140731 2019
40
Plasma cell neoplasm with varied morphology: A report of two cases. 61
31579230 2019
41
Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. 61
31189919 2019
42
[An unusual case of POEMS syndrome: in absence of clinical sign of polineuropathy.] 61
31282487 2019
43
Analysis of clinical and histopathological findings in Russell body gastritis and duodenitis. 61
31031217 2019
44
Monoclonal gammopathy of undetermined significance. 61
31010848 2019
45
Diagnosis of amyloid neuropathy. 61
30598431 2019
46
[Free light chains assay: Indications and methods]. 61
30862366 2019
47
Circulating microRNAs and Their Role in Multiple Myeloma. 61
31052608 2019
48
Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. 61
31113466 2019
49
Difference in megakaryocyte expression of GATA-1, IL-6, and IL-8 associated with maintenance of platelet counts in patients with plasma cell neoplasm with dysmegakaryopoiesis. 61
30825517 2019
50
Regression of chronic kidney disease in a patient with AL amyloidosis: A case report
. 61
30935458 2019

Variations for Plasma Cell Neoplasm

Expression for Plasma Cell Neoplasm

Search GEO for disease gene expression data for Plasma Cell Neoplasm.

Pathways for Plasma Cell Neoplasm

GO Terms for Plasma Cell Neoplasm

Cellular components related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 SDC1 PTPRC NCAM1 CD40LG CD38 B2M
2 external side of plasma membrane GO:0009897 9.23 SDC1 PTPRC NCAM1 IGHV4-38-2 ICOSLG CD79A

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.89 MYC MAEA IL6 CD40LG CD38
2 regulation of immune response GO:0050776 9.73 ICOSLG CD40LG CD19 B2M
3 immune system process GO:0002376 9.73 POLR3E IRF4 ICOSLG CD79A CD19 B2M
4 B cell differentiation GO:0030183 9.63 PTPRC CD79A CD40LG
5 interferon-gamma-mediated signaling pathway GO:0060333 9.58 NCAM1 IRF4 B2M
6 positive regulation of T cell proliferation GO:0042102 9.54 PTPRC IL6 CD40LG
7 negative regulation of bone resorption GO:0045779 9.52 IL6 CD38
8 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.51 PTPRC IRF4
9 regulation of B cell receptor signaling pathway GO:0050855 9.48 PAX5 CD19
10 T cell activation GO:0042110 9.33 PTPRC IRF4 ICOSLG
11 T-helper 17 cell lineage commitment GO:0072540 9.32 IRF4 IL6
12 B cell proliferation GO:0042100 9.13 PTPRC CD79A CD40LG
13 B cell receptor signaling pathway GO:0050853 9.02 PTPRC IGHV4-38-2 CD79A CD38 CD19

Sources for Plasma Cell Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....